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Summary
Oral anticoagulant therapy has been shown to be effective for
scveral indications. The optimal intcnsity of anticoagulation for
each indication, howcver, is largely unknown. To determinc this
optimal intensity, randomiscd clinical trials are conducted in
which two target levcls of anticoagulation are compared. This
approach is incfficicnt, since the choice of the target levels will bc
arbitrary. Moreover, the achieved intcnsity is not taken into
account.
Wc propose a mcthod to determine the optimal achieved
intensity of anticoagulation. This method can bc applied wilhin a
clinical trial äs an "efficacy-analysis", but also on data gathered in
day-to-day paticnt carc.
In this method, INR-specific incidence ratcs of events, either
thromboembolic or hemorrhagic, are calculated. The numerator
of the incidence rate is based on data on the INR at the time of the
cvent. The denominator consists of the pcrson-time at each INR
value, summed over all patients, and is calculated from all INR
measurements of all patients during the follow-up interval. This
INR-specific person-time is calculated with the assumption of a
linear incrcase or decreasc between two consecutive INR deter-
minations. Since the incidence rates may bc substratificd on
covariates, efficient assessmcnt of the effects of other factors (e. g.
agc, scx, comedication) by multivariale regression analysis
bccomes possiblc.
This method allows the determination of the optimal phar-
macological effects of anticoagulation, which can form a rational
starting point for choosing the target levels in subscquent clinical
trials.
Introduction
Several randomiscd clinical trials have been conducted, or are
in progress, in which two intensities of oral anticoagulant therapy
are compared prospcctively. This unfolding array of trial activity
prescnts two problems to the field. First, it is unclcar how the
target levels of anticoagulation which are contrasted in these trials
are predcfined. Up to now, the choice of target levcls is largely
arbitrary and thcreforc a sheer infinite scries of "trial and error"
will inevitably follow. Second, the actually achieved intensity of
anticoagulation is not taken into account. At best, the achieved
intensity will fluctuatc around the target levcl in a way that is
dependcnt on particular patient characteristics and local Organisa-
tion of anticoagulation monitoring. These randomiscd trials
thcrefore offer only littlc Information about the optimal intensity
of anticoagulation, for the pharmacologic effect and the effects of
extrancous lactors influcncing anticoagulation are incxtricably
intertwined.
Concspondcncc lo. Di. F. R. Roscndaal, Depaitmcnt ot Clinical
Epidemiology, Bldg l, CO-P, Umvcisity Hospital Leiden, P.O Box
9600, NL-2300 RC Leiden, The Ncthcilands
The efficacy of oial anticoagulant treatment has been un-
cquivocally dcmonstrated for scveral indications. These include
short term prophylaxis for venous thrombosis in high-risk situa-
tions, and short term treatment after an episode of deep venous
thrombosis or pulmonary embolism. Long term treatment has
bccn shown to bc bencficial in patients with mechanical heart
valvcs, in patients with atrial fibrillation, and in patients suffering
from coronary artery discasc (1). For all these indications
anticoagulant treatment has proved to be effective compared to
placebo. The ncxt question is which intensity of anticoagulation
offers the best benefit-risk-ratio, i.e., the optimal balance
between thrombosis prevention and the occurrence of bleeding
complications. This issue has gained rclevance since the develop-
ment and Implementation of the ISI/INR System, which renders it
possible to cxprcss the anticoagulation level, äs measured
routinely and locally with one of the many available thromboplas-
tins, in one standardised measure (2).
Some of the trials in which two levcls of anticoagulation were
compared, for instance in patients with bioprostheses of the heart
valves (3) and in patients with mechanical heart valves (4), have
shown target levels lower (i.e. less anticoagulation) than those
usually recommended to be äs effective and äs safe äs the higher
target levels. All these trials are obviously of the intention-to-
treat type, since it is impossible to maintain a completely stablc
anticoagulant effect at the target level in all patients all of the
time. Extraneous factors äs patient's compliance, physician's
experience and variations in cumarin sensitivity in the individual
paticnt will causc differences between the achieved intensity and
the target level. Therefore, little insight is obtained about the risk
of untoward effects at different intensities of anticoagulation.
This can be illustrated by the study of Saour et al. (4), who
compared target levels of INR 2.65 and INR 9.0 in patients with
mechanical heart valves. In this study 33 thromboembolic events
and 13 major bleedings were observed. The thromboembolic
events were equally divided over both treatment groups, whereas
most bleedings occurrcd in the group with the high target level.
However, two-thirds of all thromboembolic events occurred at
anticoagulation intensities (at the time of the event) below
INR 2.65 and all occurrcd at intensities below INR 9.0. Similarly,
in ninc of the 13 patients with major bleeding, the anticoagulation
intensity exceeded INR 14 at the time of the event. So, most
complications occurred in patients in whom the achieved intensity
of anticoagulation at the time of the evenl was far from the
intended intensity. In addition, one may question the generalisa-
bility from the results of a study of this design to other centers,
since patient compliance and quality of anticoagulation monitor-
ing may be quite different.
We propose a method to determine the optimal achieved
intensity of anticoagulation. In our view, this method should not
replacc, but precede trials in which target levels are compared,
since knowledge of this optimal achieved intensity offers a
rational starting point for setting the target levels in subsequent
trials. In addition, our method will yield insight into the variability
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dt different taiget levels in a care System which is dcdicated but
still belongs to medical routine
Method
Tho pioposcd mcthod mvolvcs tho calculation of mcidcncc latcs öl
both typcs oi untowaid cvcnts (thiombocmbolism and blccding) loi
ditfcicnt achicvccl mtcnsitics of anticoagulation To pcifoim thcsc calcu
lations, a study timc f iamc has to bc dcdncd ovci which a cohoit oi
paücnts is obscivcd The rcquircd inloimation includc Ihc datcs ot all
piothiombin timc asscssmcnts and thc icsults ot Ihcsc mcasuicmcnts
dui ing thc obsoivation timc, äs well äs thc datcs of all cvcnt occuiicnccs
and thc piothiombin timcs at thc timc öl thc cvcnts Covanatcs, cithci
gencial such äs agc and gendci 01 spccific such äs hypeitcnsion, atnal
tibnllation 01 co medication may be icgistcicd and mcoipoialcd by
stiatiticd analysis 01 multivaiiatc modclmg by Poisson icgicssion Bctoic
dcscubing thc spccilic apphcation ot thc calculation ot mcidcncc latcs in
anticoagulatcd paticnts, wc will discuss thc conccpts ot mcidcncc latcs and
thc catcgonsation ot mcidcncc latcs
Incidence Rates
Mathcmatically, thc mcidcncc latc (mcidcncc dcnsity 01 hazaid lalc) is
Ihc instantancous piobability ot an cvcnt occuncncc Thc avciagc
mcidcncc latc is thc numbci of cvcnts dividcd by thc obscivation timc,
ususally cxpicsscd m paticnt-ycais It appioximatcs thc instantancous
mcidcncc latc by thc assumption that ovci short obscivation intcivals Ihc
piobability oi discasc is piopoitional to thc obscivation timc, i c ,
10 paticnts tollowcd toi 2 ycais will yicld thc samc mcidcncc äs
20 paticnls tollowcd loi l ycai Undci this assumption, thc mcidcncc täte
is casily calculatcd by dcteimmmg thc numbci of evcnts and dividing this
tiguic by thc s u m of thc obscivatiön timcs of all paticnts m thc cohoit (5)
Foi cach individual paticnt, thc obscivation timc is countcd tiom his cntiy
in thc study until cithci thc cnd ot Ihc study timc fiamc 01 thc timc of an
cvcnt, whichcvci occuis tust Thc piobability of an cvcnt ovci a ccitam
timc mtcival (cumulative mcidcncc) can bc dcnvcd tiom thc mcidcncc
latc by a simple cxponcntial tianstoimation (5, 6)
Calegoii^ation of the Obieivation Time
In thc simplest foim, thc mcidcncc is calculated foi onc, unstiatificd
cohoit, by dividing the numbci oi cvcnts by thc sum ot thc obscivation
timcs of all patients m thc cohoit A first cxtcnsion is stiatitication ovci
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Fig l Allocation öl pcison-timc at diltcicnt INRs Six prothiombm timc
asscssmcnts and thc datcs of thcsc asscssmcnts aic shown ioi onc paticnt
Thc timc clapscd bctwccn two mcasuicmcnts is dividcd ovci thc INRs of
thcsc two asscssmcnts äs mdicatcd in thc uppci nght Thc pcison-timc
will subscqucntly bc dividcd ovci thc picdcfmed cclls, i c , INR 2 5-2 9
28 0 days INR 3 0-3 4 24 5 days, INR 3 5-3 9 10 5 days and
INR 4 5-4 9 1 4 0 days
fixcd covanatcs, such äs scx In this casc all mcn conlnbutc pcison timc
only to Ihc male stialum and all womcn only to thc tcmalc stiatum, with
Ihc icsult ot two scx-spccilic mcidcncc latcs
Smcc, howcvci thc only constitucnts öl thc mcidcncc latcs aic thc
stiatum-spccitic numbci of cvcnts, and thc stiatum-spccitic total obsciva
tion limc, it is not icquncd that paticnts only contnbutc paticnt-timc to
onc stiatum Whcn stiatification is pcitoimcd on untixcd covanatcs, such
äs calcndai-pciiod oi agc äs is usually donc to allow standaidiscd
companson ot two mcidcncc latcs, onc paticnt may contubutc pcison-
tmic to scvcial stiata For mslancc, if 5-ycai agc catcgoncs aic uscd and
10-ycai calcndai timc pcnods, a patient lollowcd toi 5 ycais, staitmg in
1988 at agc 42 will contnbutc 2 ycais pcison timc to Ihc ccll
[40-44 ycais, 1980-1989], l ycai to thc ccll [40-44 ycais, 1990-2000]
and 2 ycars to thc ccll [45-49 ycais, 1990-2000] Agc- and calcndai-
pcnod spccilic mcidcncc latcs aic subscqucntly calculatcd äs thc numbci
ot cvcnts withm cach ccll, dividcd by Ihc total obscivation timc m cach
ccll, which is dcnvcd hom scvcial paticnts
Application to the Level of Anticoagulation
Fully analogous lo thc catcgonsation ot thc pcison timc in cclls
clctcimmcd by agc scx and calcndai pcnods, thc obscivation timc may bc
biokcn down in cclls of thc achicvcd Icvcl of anticoagulation Thc
mcidcncc latc ot cvcnts at cach Icvcl öl anticoagulation is agam calculatcd
äs thc ratio ot thc numbci ot cvcnts occuinng at a paiticulai mtcnsily,
ovci thc summcd pcison timc at that mtcnsity
Evenls at Each Level (Incidence Numeiatoi)
Dcpcndcnt on thc cvcnts thc study is aimed al, a System has to bc sct
up m which all cvents aic icgistcicd It sccms most piactical lo limit thc
study to scverc complications i c those that icqune hospitahsation 01
Icad to dcath Ideally, onc has to know thc mtcnsity ot anticoagulation at
thc timc of thc cvcnt In casc ot hospitahsation, a piothiombin timc will
usually bc pcrfoimcd Whcn this has not bccn donc thc only appioxima
tion ot the anlicoagulation Icvcl a thc timc of thc cvcnt is that of thc last
mcasuicmcnt bctoic thc cvcnt occuiied
Calculation of ihe Obieivation Time foi Diffeient Levels
(Incidence Denominatoi)
Foi cach paticnt, piothiombin timcs have bcen mcasuicd at fixcd 01
vanablc mtcivals, thc Icngth of which timc mtcivals is known Wc assumc
that thc INR valuc bclwccn two mcasuicments will vaiy Imcaily tiom thc
valuc ot thc tust, lo thc valuc of thc sccond mcasuicmcnt With this
assumption, two appioachcs may bc cmploycd to allocatc the peison-Ume
bctwccn two mcasuicmcnls lo paiticulai INR valucs Thc most simple
appioximation is to clividc thc timc betwccn two mcasuicmcnt in halvcs,
and allocatc thc tust halt to thc INR valuc oi thc fnst, and thc sccond halt
lo thc INR valuc of thc second measuicmcnt So, it a 2-weck mtcival is
boundcd by a piothiombin Urne of 3 6 INR äs Ihe tust, and 4 3 INR äs
thc sccond mcasuicmcnt, l weck of pcison-time is allocatcd to 3 6 INR,
and l wcek to 4 3 INR This is illustiatcd by Fig l Subscqucntly thc
pcison-timc at cach INR valuc is summcd ovci all mcasuicmcnts ot all
paticnls, and thcn gioupcd mto cclls ot 0 5 01 10 INR Although m this
appioximation thc INR is ticalcd äs if it changes mstanlly haliway
bctwccn two measuicmcnls, ovci laigc numbci s il yiclds a tan appioach
lo thc assumption ot a Imcai mcicasc 01 dccicasc (Fig 2)
A sccond, moic accuratc appioach is lo dividc Ihc Urne bctwccn two
mcasuicmcnts in days, and lo usc small stcps ot 0 l INR ovci thc lange ot
thc timc mlcival In llus appioach, Ihc INR is licalcd äs giadually
mcicasmg 01 dccicasmg ovci Ihc mtcival In thc cxamplc abovc, 2 days
aic allocatcd lo an INR ot 3 6, 2 days to an INR ot 3 7, and so on
Subscqucnlly, Ihc pcison limc of thcsc small stcps is collapscd mlo laigei
cclls of 0 5 oi 1 0 INR and Ihcn summcd ovci all palicnls Wc havc
dcvclopcd Software lo pciloim Ihcsc calculations on a pcisonal com-
pulci !
Fig 2 shows Ihc icsulls of Ihc apphcalion oi bolh appioachcs lo Ihc
dala ot 392 paticnts wilh mcchanical hcait valvcs who visilcd Ihc Leiden
Thiombosis Scivicc bctwccn 1985 and 1991 (lolal obscivalion limc
Nolc Thc sotlwaic can bc madc availablc on icqucsl
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Fig 2 Allocation ot 1NR spcciüc pcison-limc ot 392 paticnls with mechanical hcait valvcs The aclucvcd intcnsity, in pcison ycais at diticicnt INR
valucs, is shown toi 392 paticnts ( l 297 paticnt ycais) with mechanical hcai t valvcs who wci c tollowcd betwccn 1985 and 1991 Foi the uppci pai t of thc
üguic, thc appioach dcpictcd in Fig l has bccn cmploycd, m which halt ot thc timc clapscd betwccn two visits is allocatcd to thc tust, and halt to thc
sccond rncasuicmcnl Foi thc lowci pait thc appioach ot a tiuly hncai incicasc 01 dccieasc was used, in which thc INR is calculatcd toi cach day öl thc
mtcival Foi both paits ot thc iiguic, thc icsults have bccn icgioupcd in 0 5 INR mtcivals. and thc days havc bccn convcitcd to jcais
1,297 ycais) Both appioachcs yicld vciy similai icsults, albcit that with
thc appioach in which the timc bctwccn two mcasuicmcnts is dividcd in
halves, shghtly moic pcison-timc is accumulatcd at thc exticmc valucs
Analysis
Smcc the numbci ot events at cach intcnsity and thc summcd pcison-
time at cach intcnsity aic now known, mcidcncc lales at cach intcnsity can
bc calculatcd Thc cclls may bc luithci sliatified by scx, agc and othci
covaiiatcs, and by application oi a multivaiialc Poisson icgicssion modcl
incidcnce lato latios at the ditteicnt mtcnsitics may bc calculated, to
contiol loi contounding by this covaiiatcs and to cxaminc thc nsk ot
comphcations associatcd with thcsc covanates Standaid cnois toi thc
mcidcncc latcs and thc mcidcncc lato latios can bc dcnved in thc standaid
tashion bascd on thc assumption ot a Poisson distnbution ot thc numbci
of cvents These multivauatc analyscs can bc pcitoimcd by sevcial ot thc
commcicially availablc soltwaic packagcs
In thc sccond study, wc usc this mcthod to mvestigate nsk factois toi
blccdmg m unsclcctcd paticnts who icceive anticoagulant trcatment foi
vanous mdication (8) To this cftect, wc study mmoi and ma]Oi bleedmg
comphcations duimg l ycai m thc ovci 6,800 patients tieated by the
Leiden Thiombosis Scivicc annuall) In this mstancc, the mcthod scivcs
two puiposcs Fnst wc exammc the nsk ot blccdmg toi ditteicnt
mtcnsilics ot anticoagulation Second wc can by multivauatc analysis,
usc thc mtensitics äs an ad|ustmcnt tactoi and mvcstigale thc contnbution
ot othci tactoi s to the nsk ot blccdmg mdcpcndcnt ot thc aclucvcd
intcnsity ot anticoagulation
Yet anothci application ot this mcthod is äs a mcasuic foi the quality
of anticoagulation monitonng which is now usually given äs thc pciccnt
agc of piothiombm timcs within thc taigct zones By calculating thc
peison-timc spent at cach intcnsity of anticoagulation wc can cxpicss thc
quality öl monitonng äs thc pciccntagc of thc total pcison timc that lies
within thc taigct zoncs
Application of the Melhod
This mcthod can bc apphcd ictiospectivcly, on data loutincly icgis-
teicd by a thiombosis scivtcc, äs well äs piospcctivcly äs a secondaiy
analysis within a landomizcd lnal Thc method is piescntly cmploycd in
two studies In thc tust onc, thc Leiden Aititicial Valves and Anlicoagula
tion study (LAVA), wc scck thc optimal intcnsity ot achieved anücoagu
lation m paticnts with mechanical hcail valvcs äs thc Icvcl at which thc
mcidcncc ot stiokc, combinmg intaiclion and bleedmg, is lowcst Smcc
the nsk ot thiombosis on a mechanical valvc and subscqucnl ccicbial
cmbohsm is high in thc abscncc öl anticoagulation ticatmcnt (appioxi-
malcly 1-5% pei yeai), paticnts with mechanical hcait valvcs aic
mtcnscly anticoagulatcd (taigct lange m Thc Nctheilands 3 6-4 8 INR)
This imphcs that thc nsk öl majoi blcedmgs, ot which ccicbial hemoi
ihagc is the most scvcic, is iclativcly high, and thc balancc bctwccn
thiombosis piophylaxis and iisk of blccdmg piccious It is icasonablc to
assumc lhat thc nsk of ccicbial cmbohsm and mtaiction mcieascs with
lowci mtensitics ot anticoagulation, whcicas thc nsk ot ccicbial blccdmg
mcieascs with highci mtcnsilics (Fig 3) So, wc cxpcct that thc mcidcncc
ot stiokc will havc a U-shapcd distnbution ovci the lange oi aclucvcd
mtensitics Piclimmaty icsults mdicatc that this U-shapcd distnbution
docs cxist (7) Foi this analysis, it is not cvcn ncccssaiy to distinguish
bctwccn ccicbial mfaictions and ccicbial blccdmg and it avoids thc
ditticult task ot classitymg a hcmonhagic inlaiction äs cithei mtaiction 01
bleedmg Smcc wc aic mtcicsted in the level ot anticoagulation that has
thc lowcst i isk ot stiokc, whatevci its oiigm, it is ot moie iclcvancc to usc
a chnical classitication System bascd on thc scventy ot thc scquclac ot the
stiokc
Inoidence rates
Intensity of OAC
Fig 3 Thcoictical iclation öl the mcidcncc öl thiombocmbohsm and
blccdmg with thc achieved intcnsity öl anticoagulation Thc iisk ot
thiombocmbohsm dccicascs exponentially with incicascd mtensitics of
anticoagulation, whcicas thc nsk of bleedmg mcieascs exponentially Thc
lowcst mcidcncc öl untowaid cttccts ι c thc m m i m u m of thc supciim
poscd giaphs, dcnoles thc optimal intcnsity of anticoagulation
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Discussion
We have proposed a method that allows assessment of the
optimal achievcd intcnsity of anticoagulation by the calculation of
INR-specific mcidence ratcs of untoward evcnts The rcsults of
analysis by this method can bc used to sct the target rangcs for
chnical tuals on oral anticoagulation tor vanous indications In
addition, the method can bc cmployed to detcrmme nsk factors
for comphcations, thiombosis or blccdmg, adjusted for the
achieved level of anticoagulation
A prcrequisite for the usc of this method is careful observation
of all complication If, howevcr, this is donc routincly, äs in the
Dutch Thiombosis Seivices, and if dates and lesults of prothrom-
bm time mcasurements are stored in compuleis over longer
penods of time, this method can bc apphcd rctiospcctively to
large numbers of patients, and precise estimates may bc expected
One of the assumptions of the allocation of person-time to
diffeient mtensitics of anticoagulation is a linear mcrease or
decrease of the anlicoagulation effect between subsequcnt mcas-
urements It may well be, however, that the change is greatest
shortly aftcr a measuiement has been performed and a dose
adjustment has been made, in particular when a prothrombm
mcasurcment shows excessive under- or overanticoagulation, in
which casc a boostei-dose or Vitamin K may be prescnbed We
feel that these effects will probably cven out m the broad ränge
aiound the target values, encompassmg the majonty of mcasuie-
ments This is especially so since the INR categones are broadly
chosen, with mtcivals of 0 5 or l 0 INR For extreme values,
there may be a bias, with an overcstimatc of the pcrson-timc at
vcry Iow, and at very high INR values This imphcs that the
mcidence ratcs at thesc extremes will be undeiestimated Since
the optimal Icvcl will not be located at these extreme values, we
considei this of minor importance It must bc notcd that this
leasoning becomes Icss vahd whcn anticoagulation contiol is of
veiy pooi quahty, i e when all stabihty in anticoagulation is
lacking
Assessment of the optimal achieved level öl anticoagulation
should precede studies comparing diffeient target levels Since it
is not possible to maintam an optimal level m all patients
constantly, subsequcnt chnical tnals lemain nccessaiy, to evalu-
ate target levels set at or around the optimal achieved intensity on
an intention-to-treat basis
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